Olopatadine nasal spray for the treatment of allergicrhinitis

Peter S. Roland, Bradleyf Marple, G. Michael Wall

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Olopatadine hydrochloride nasal spray (Patanase® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

Original languageEnglish (US)
Pages (from-to)197-204
Number of pages8
JournalExpert review of clinical immunology
Issue number2
StatePublished - Mar 2010


  • Allergic rhinitis
  • Allergic rhinosinusitis
  • Antihistamine
  • Mast cell stabilizer
  • Nasal spray
  • Olopatadine hydrochloride
  • Patanase

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Olopatadine nasal spray for the treatment of allergicrhinitis'. Together they form a unique fingerprint.

Cite this